The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMM01 plus tislelizumab in patients with advanced solid tumors and lymphoma: An open-label, multicenter, phase 1b/2 dose escalation and expansion study (IMM01-04).
 
Zhengbo Song
No Relationships to Disclose
 
Xu Tong
No Relationships to Disclose
 
Yan Zhang
No Relationships to Disclose
 
Hui Zhu
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Xiaoqing Yu
No Relationships to Disclose
 
Xinghao Ai
No Relationships to Disclose
 
Zhenzhen Zong
Employment - ImmuneOnco Biopharmaceuticals
 
Xiwen Zhao
Employment - ImmuneOnco Biopharmaceuticals
 
Siman Gao
Employment - ImmuneOnco Biopharmaceuticals
 
Qiying Lu
Employment - ImmuneOnco Biopharmaceuticals
Stock and Other Ownership Interests - ImmuneOnco Biopharmaceuticals
 
Wenzhi Tian
Employment - ImmuneOnco Biopharmaceuticals
Leadership - ImmuneOnco Biopharmaceuticals
Stock and Other Ownership Interests - ImmuneOnco Biopharmaceuticals
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)